Teva Halts High Dose MS Trials Over Heart Issues

Source: Wall Street Journal

Jan 07, 2016

Teva Pharmaceutical and Active Biotech announced they were ending the higher-dose portions of two multiple-sclerosis studies involving the drug Laquinimod, after patients suffered non-fatal "cardiovascular events."

The incidents occurred in 8 patients involved in the higher-dose components of a phase 3 and phase 2 clinical trial. Trials of the once-daily oral drug laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.

Teva had set its hopes on Laquinimod to be its next potential multiple-sclerosis blockbuster, after Copaxone lost patent protection last year.

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments